Boomerang Medical’s IBD Neuromodulation Study Successfully Completes Enrollment Milestone

Boomerang Medical’s IBD Neuromodulation Study Successfully Completes Enrollment Milestone




Boomerang Medical’s IBD Neuromodulation Study Successfully Completes Enrollment Milestone

Pioneering Bioelectronic Research Advances in the Fight Against Inflammatory Bowel Disease




MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Boomerang Medical, Inc., a women-led bioelectronic medicine company focused on autoimmune diseases, proudly announced the completion of Stage 2 of its FDA-approved pilot study. This milestone marks a significant advance in the company’s research as it progresses towards its pivotal study. The BOOM-IBD Clinical Trial, the first prospective, multicenter study of its kind in the United States to explore the use of a bioelectronic technology designated as a Breakthrough Device by the FDA for inflammatory bowel disease (IBD), has garnered substantial patient and physician interest.

The clinical trial has successfully enrolled patients with Crohn’s disease and ulcerative colitis–the two most common forms of IBD–at multiple locations across the United States, including renowned research institutions like Mount Sinai, Columbia Irving Medical Center, and the University of Pennsylvania. The Comprehensive Digestive Institute of Nevada enrolled the last patient in the study.

“This study represents a promising step forward in the quest for expanding the armamentarium for managing IBD. Our participation underscores our dedication to advancing patient care, and we are eager to contribute valuable insights that could advance the future management of IBD,” said Christian Stone, MD, MPH, principal investigator at the Comprehensive Digestive Institute of Nevada.

IBD stands as one of the most debilitating autoimmune diseases, affecting millions globally. Living with ulcerative colitis or Crohn’s disease impacts not just physical health but also work, relationships, and well-being. While existing therapies have made significant strides in managing IBD, the complexity of the condition means that there is always room for innovative approaches.

Heather Simonsen, CEO of Boomerang Medical, commented on the recent milestone: “Successfully completing the Stage 2 enrollment for our BOOM-IBD Clinical Trial is a significant step in our research trajectory. Our heartfelt appreciation goes to the BOOM-IBD investigational sites for their dedicated efforts in this critical research.”

For more information, please visit www.boomerangmedical.com.

​​About the Comprehensive Digestive Institute of Nevada

Comprehensive Digestive Institute of Nevada’s patients will receive the highest quality digestive care. Our gastroenterology experts have outstanding clinical expertise, board certifications, academic backgrounds, international recognition, as well as a compassionate approach. They are sought out as trusted and reliable professionals throughout the regional medical community. CDIN is dedicated to providing exceptional, personalized, and empathetic patient care in every way—from consultations, testing, care plan, procedures, to continual care as needed. We continue to develop and enhance methods to improve each patient’s experience. Along with our highly experienced physicians, our staff also works diligently to maintain the highest standards for trusted medical care and patient satisfaction. Some of our services include colonoscopy, endoscopy, treating abdominal pain, and treating diarrhea and constipation.

For more information about the Comprehensive Digestive Institute of Nevada, visit https://www.nevadagastro.com/.

About Boomerang Medical, Inc.

Boomerang Medical is a women-led bioelectronic medicine company on a mission to disrupt the treatment of autoimmune diseases. The company is developing a bioelectric neuromodulation technology, which has been granted Breakthrough Device Designation by the FDA for the treatment of Crohn’s disease and ulcerative colitis. Boomerang Medical is headquartered in the heart of Silicon Valley on the campus of El Camino Hospital in Mountain View, California. We are proud to be a Company–In-Residence at the prestigious Fogarty Innovation incubator–the only healthcare-focused incubator of its kind in the US–giving us access to the brightest minds and expertise in the medical technology industry. Current investors in the company include Arboretum Ventures and Hatteras Venture Partners. For more information, visit www.boomerangmedical.com.

Contacts

Braden R. Koch

info@boomerangmedical.com